FDA Inspection
Modavar PharmaceuticalsModavar Pharmaceuticals – FDA Inspection, Jan 27, 2023
Record Details
This FDA Inspection record concerns Modavar Pharmaceuticals, with an inspection on January 27, 2023, issued by the Baltimore District Office.
- Company
- Modavar Pharmaceuticals
- Inspection Date
- January 27, 2023
View Company Profile
ID · d26160e6-dfa9-4457-8cd6-d8724c6675ac
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1196541
- FDA center
- Human Drugs
- Project area
- Generic Drug Evaluation
- Outcome
- Form 483 issued
FDA Citations
8- 21 CFR 211.111Establishment of time limitations
- 21 CFR 211.160(b)(2)In-process sample representation/identification
- 21 CFR 211.166(a)(1)Sample size - test intervals
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.68(b)Backup file not maintained
- 21 CFR 211.84(d)(2)Component written specification
- 21 CFR 211.68(b)Computer control of master formula records
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Modavar Pharmaceuticals
1| Date | Classification | Office | Project area |
|---|---|---|---|
| November 15, 2024 | Not classified | Baltimore District Office |
Other documents for Modavar Pharmaceuticals
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.